

	PRICE DROP				
--	------------	--	--	--	--

Home > News > Industry > Pharma News > Dr Reddys, Prestige...

Dr Reddys, Prestige BioPharma Ink Pact For Trastuzumab Biosimilar Commercialization In Select Countries



Ruchika — Published On 10 Dec 2021 1:24 PM | Updated On 10 Dec 2021 1:24 PM

Medical News ▾ Health News ▾ Medical Guidelines ▾ AYUSH ▾ State News ▾ Medical Education ▾

Latest



RESOUR
EDUC
ELSE
Know M

Medica



Singapore: Prestige BioPharma Ltd. and Dr. Reddy's Laboratories Ltd. have announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma's proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.

Prestige BioPharma's trastuzumab (HD201) is a proposed biosimilar to Roche's Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer.

Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.

TOP

Medica

10 Dec



Health |

The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia.

Under this partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from manufacturing facilities in Osong, South Korea, while Dr. Reddy's will be responsible for local registration, marketing and sales in the licensed territories.

Lisa S. Park, CEO of Prestige BioPharma, commented: "We are delighted to establish a partnership with Dr. Reddy's for key Latin American and Southeast Asian markets. Dr. Reddy's is the ideal partner to commercialize our biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets."

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy's, said: "In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need. Our partnership with Prestige BioPharma will help us combine their established expertise in the area of biosimilars with our commercial strengths and growth ambition in these markets. This is in line with our intention to create a portfolio of oncology products and expand our biosimilar offerings in Emerging Markets."

Medical News ▾ Health News ▾ Medical Guidelines ▾ AYUSH ▾ State News ▾ Medical Education ▾



prestige biopharma

prestige biopharma news

trastuzumab

roche

herceptin

breast cancer

metastatic gastric cancer

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd



Ruchika

Ruchika joined Medical Dialogue as a Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Similar Posts

NPPA panel fixes retail price of Sun Pharma Cyclosporine, Details

Dr Reddys seeks DCGI nod for Sputnik Light phase 3 trial as booster dose

Alembic announces seed round investment in RIGImmune, Inc. Alembic Pharma invests in RIGImmune

Healthium Medtech launches CDSCO-certified facility in Ahmedabad

COVID vaccination likely to hit as syringe plants in Faridabad


New USFDA approved eye drops Vuity could be life-changer for

Gland Pharma bags USFDA nod for Cangrelor for Injection

UK MHRA okays Marksans Pharma anti-diarrhoea drug



Medica



Medica
10/Dec

